Maternal Pertussis Immunization and Immunoglobulin G Levels in Early- to Late-Term and Preterm Infants
Open Access
- 1 July 2024
- journal article
- research article
- Published by American Medical Association (AMA) in JAMA Network Open
- Vol. 7 (7) , e2424608
Abstract
Importance: Maternal tetanus, diphtheria, and acellular pertussis (Tdap) vaccination protects newborns against severe pertussis. Data on transplacental antibody transfer on Tdap vaccination before 24 weeks’ gestation remain scarce and are particularly relevant for preterm infants to increase the time interval for maternal antibody transfer.Objective: To assess noninferiority of anti–pertussis toxin (anti-PT) immunoglobulin G (IgG) antibody levels at age 2 months in early- to late-term infants following Tdap vaccination between 20 0/7 and 24 0/7 weeks’ gestation compared with 30 0/7 and 33 0/7 weeks’ gestation and compared with preterm infants.Design, Setting, and Participants: This prospective, multicenter cohort study included pregnant women aged 18 years or older in birthing centers and hospitals in the Netherlands between August 2019 and November 2021 who received Tdap vaccination between 20 0/7 and 24 0/7 weeks’ gestation. Women with imminent premature birth were recruited if they had received maternal Tdap vaccination between 20 and 24 weeks’ gestation. Blood samples were collected from mothers at delivery, from the umbilical cord, and from infants at age 2 months. Data from infants’ blood samples at age 2 months were compared with a reference cohort (recruited between January 2014 and February 2016) of early- to late-term infants of the same age whose mothers had received Tdap vaccination between 30 0/7 and 33 0/7 weeks’ gestation.Exposure: Maternal Tdap vaccination between 20 0/7 and 24 0/7 weeks’ gestation or 30 0/7 and 33 0/7 weeks’ gestation.Main Outcomes and Measures: The primary outcome was the geometric mean concentration (GMC) of anti-PT IgG antibodies in early- to late-term infants (≥37 0/7 weeks’ gestation) at age 2 months, comparing maternal Tdap vaccination between 20 0/7 and 24 0/7 weeks’ vs 30 0/7 and 33 0/7 weeks’ gestation (reference cohort). Anti-PT GMC in 2-month-old infants born preterm (P = .23 compared with early- to late-term infants).Conclusions and Relevance: In this cohort study, 2-month-old preterm and early- to late-term infants showed significantly lower anti-PT antibody levels following maternal Tdap vaccination between 20 0/7 and 24 0/7 weeks’ gestation compared with 30 0/7 and 33 0/7 weeks’ gestation; preterm and early- to late-term infants had similar anti-PT antibody levels, but both groups showed significantly lower antibody levels compared with the reference group. Epidemiological research should investigate whether maternal Tdap vaccination before 24 weeks’ gestation provides sufficient protection against clinical pertussis, particularly in preterm infants, as long as no correlate of protection is available.Keywords
This publication has 30 references indexed in Scilit:
- Decay of anti-Bordetella pertussis antibodies in women of childbearing age following COVID-19 non-pharmaceutical measuresVaccine, 2022
- Short term impact of the COVID-19 pandemic on incidence of vaccine preventable diseases and participation in routine infant vaccinations in the Netherlands in the period March-September 2020Vaccine, 2021
- Association Between Third-Trimester Tdap Immunization and Neonatal Pertussis Antibody ConcentrationJAMA, 2018
- The optimal gestation for pertussis vaccination during pregnancy: a prospective cohort studyAmerican Journal of Obstetrics and Gynecology, 2016
- The avidity of pertussis antibodies following gestational acellular pertussis immunization: Reply to MaertensVaccine, 2015
- Immunization of pregnant women against pertussis: The effect of timing on antibody avidityVaccine, 2015
- The effect of timing of maternal tetanus, diphtheria, and acellular pertussis (Tdap) immunization during pregnancy on newborn pertussis antibody levels – A prospective studyVaccine, 2014
- World Medical Association Declaration of HelsinkiJAMA, 2013
- Development and validation of a multiplex immunoassay for the simultaneous determination of serum antibodies to Bordetella pertussis, diphtheria and tetanusJournal of Immunological Methods, 2008
- A search for serologic correlates of immunity to Bordetella pertussis cough illnessesVaccine, 1998